{"id":332822,"date":"2026-10-29T19:20:54","date_gmt":"2026-10-29T13:50:54","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/strides-pharma-science-q2-results-fy27-pat-134-crore\/"},"modified":"2026-10-29T19:20:54","modified_gmt":"2026-10-29T13:50:54","slug":"strides-pharma-science-q2-results-fy27-pat-134-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/strides-pharma-science-q2-results-fy27-pat-134-crore\/","title":{"rendered":"Strides Pharma Science Q2 Results FY27: Revenue Rises 17.11% to Rs 1,429.73 Cr, PAT Up 1.98% to Rs 134.12 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Strides Pharma Science Q2 Results FY27 were declared on 29 October 2026 for the July to September 2026 quarter. In these quarterly results, consolidated revenue came in at Rs 1,429.73 Cr, up 17.11% from Rs 1,220.83 Cr a year earlier. Net profit rose 1.98% to Rs 134.12 Cr from Rs 131.52 Cr, while Operating Profit reached Rs 250.91 Cr, a YoY growth of 8.35%.<\/p>\n<\/div>\n

Strides Pharma Science Ltd<\/a> (STAR) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated revenue of Rs 1,429.73 Cr and PAT of Rs 134.12 Cr into view. Strides Pharma Science Q2 Results FY27 therefore pair 17.11% revenue growth with a 1.98% rise in profit after tax, measured against the same quarter last year.<\/p>\n

This Strides Pharma Science Q2 Results article covers the financial highlights, the business drivers, the outlook and the risks in one connected sequence. The results analysis starts with the Financial Highlights table below, which sets each reported line beside the figure from the same quarter of last year.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n